Description: Articles on IRS private letter rulings on combination products, IRS treatment of reinsurance under section 845, and IRS waivers for failed contracts under section 7702.

Description: The 2017 Reinsurance News prize was awarded to Mick James, business development director, UK—Alternative Distribution at RGA for his article titled, “Long- Term Care—Are We Fishing in the Wrong Waters?” The article appeared in the November 2017 issue.

Description: With Chapter 20 of the National Association of Insurance Commissioners Valuation Manual (VM-20), the expansion of accelerated underwriting programs and digital distribution, new accounting standards under GAAP long-duration targeted improvements (LDTI) and International Financial Reporting Standard (IFRS) 17, along with a changing interest rate environment, companies may be looking for efficient reinsurance solutions to help address these ever changing and varied challenges. Hear highlights on how reinsurance can be utilized to address the challenges associated with managing new business strain and product competitiveness, earnings and risk management, and capital allocation efficiency. At the conclusion of the session, you will understand the various challenges being faced by direct writing companies today and where reinsurance can be leveraged to improve the returns and competitiveness of product offerings, provide flexibility in capital and tax planning, as well as balancing risk appetite and underwriting profit retention.

Description: This session from the 1983 SOA Spring Meeting discusses self-insurance and captive insurance companies including the motives for forming captive insurance companies, the captive concept as it applies to credit insurance, bank holding company captive insurers, the financial and non-financial reasons and operational considerations.

Description: As more gene and cell therapies enter the market at increasingly higher price points, they are ushering in a new era of medicine for rare diseases. Unlike most traditional therapies, gene and cell therapies typically have a short or one-time treatment administration and are anticipated to provide long-term clinical benefits. Actuaries must be prepared to assess, manage, and/or mitigate the risks associated with these therapies. This session includes three different perspectives—a regional plan, a stop loss/reinsurance carrier, and a health care consultant.

Description: 1999 SOA Annual Meeting, San Francisco. Panel of experts provided an overview of expanding insurance and reinsurance markets in Mexico and South America Argentina, Brazil, and Chile and the North American offshore market. They explained the role of reinsurance in these markets, including development, growth, products, solvency/capital requirements, financial reporting, and regulatory aspects.

Description: CEOs of four of the world's leading life reinsurance companies discuss their views on the directions in which the life reinsurance industry is heading. Topics include an explanation of how changes in the world are impacting reinsurers and what actions are being taken by reinsurers to deal with these changes. From the 2002 Record of Society of Actuaries, Volume 28, No. 3. Session 107I of the Boston Annual Meeting.

Description: This panel discusses the new customers, new forms of risk-sharing and new ways of reinsuring these risks. It also looks at the future in this rapidly changing market. From Record of Society of Actuaries, Vol. 22, No. 2.

Description: The presenters describe the process payers and employers can use to evaluate emerging medical device technologies, recent or pending FDA submissions for prescription drugs and experimental treatments that impact patient care, resource utilization and health care expenditures. Learn the process of identifying and selecting impactful treatments (Horizon Scanning) and quantifying the financial cost of new technologies before they arrive in the market. These workflows can be leveraged by actuaries, healthcare economists, clinicians and pharmacists from a payer (Commercial and Medicare) and employer perspective for self-funded plans. Walk through sample models that illustrate how costs for emerging technologies and treatments can be modeled.